Authentic Human Hla-a*11:01&b2m&kras G12c (vvvgacgvgk) Tetramer Protein, Ultra Low Endotoxin (mhc-hm439t-ul) Unlock 95% Savings [DLtBn4Ir]

Human HLA-A*11:01&B2M&KRAS G12C Tetramer Protein

Introducing the Human HLA-A*11:01&B2M&KRAS G12C Tetramer Protein, a cutting-edge research tool designed for advanced immunological studies. This ultra-low endotoxin protein is meticulously crafted to ensure the highest quality and reliability in your experiments. With its exceptional purity and specificity, this tetramer protein is ideal for detecting and analyzing HLA-A*11:01 and KRAS G12C antigens, making it an essential component for various research applications.

• High Purity: Our tetramer protein is produced through a stringent purification process, guaranteeing a purity level of over 95%.
• Specificity: Engineered to bind with high affinity to HLA-A*11:01 and KRAS G12C, ensuring accurate and reliable results.

Product Properties and Specifications

The Human HLA-A*11:01&B2M&KRAS G12C Tetramer Protein is designed with the latest advancements in protein engineering. It features a robust structure that maintains stability and functionality, even under challenging experimental conditions. The tetramer protein is formulated with a unique combination of B2M and KRAS G12C sequences, providing a robust platform for the study of antigen presentation and immune response.

• Stability: The tetramer protein is stable at 4°C for up to 6 months, ensuring long-lasting shelf life.
• Concentration: Available in concentrations ranging from 1 mg/mL to 5 mg/mL, catering to various experimental needs.

Practical Applications and Benefits

The Human HLA-A*11:01&B2M&KRAS G12C Tetramer Protein is a versatile tool for researchers in the fields of immunology, oncology, and virology. Its precise antigen binding capabilities make it an invaluable asset for the development of diagnostic tests, vaccine design, and therapeutic strategies. By using this tetramer protein, researchers can gain deeper insights into the immune response to HLA-A*11:01 and KRAS G12C antigens, leading to groundbreaking advancements in medical research.

• Immunological Studies: Facilitates the study of antigen presentation and immune response mechanisms.
• Therapeutic Development: Enables the design of targeted therapies and vaccines against HLA-A*11:01 and KRAS G12C.